We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 108

North Carolina Rejects Stengel in Complete Preemption Win
  • Dechert LLP
  • USA
  • July 6 2017

Put a New Yorker and a Californian in a room together and the debate will begin almost immediately. Hollywood v. Broadway. Atlantic v. Pacific

National suture class action rejected
  • Epstein Becker Green
  • USA
  • December 2 2009

The Mass Tort Defense Blog reported recently that the North Carolina federal district court overseeing the MDL concerning panacryl sutures declined last week to certify a proposed national class action in In re Panacryl Sutures Products Liability Cases.

Apotex alleges it is injured by Ranbaxy's ability to launch on schedule
  • Gowling WLG
  • USA
  • July 27 2009

In two different cases before the US District Court for the Middle District of North Carolina Apotex has alleged that Ranbaxy's inability to launch its generic versions of donepezil hydrochloride (sold by Eisai Co. under the brand Aricept) and valacyclovir hydrochloride (sold by GSK under the brand Valtrex) on time will injure Apotex.

District court dismisses class action securities lawsuit against pharmaceutical company
  • Katten Muchin Rosenman LLP
  • USA
  • February 27 2009

A district court has dismissed a class action lawsuit filed by investors in Pozen Inc. (Pozen), a pharmaceutical company, in which they alleged that Pozen, its CEO and several other officers violated Sections 10(b) and 20(a) of the Exchange Act.